Storia in 2 fonti

Why This DNA Tester Plummeted 40%, Leading A Medtech Selloff

Medical research stocks took a bath Thursday, helped by BillionToOne's report, featuring a beat but no guidance hike.

Raccontata da

benzinga.com

investors.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo16 h fa

Why This DNA Tester Plummeted 40%, Leading A Medtech Selloff

Medical research stocks took a bath Thursday, helped by BillionToOne's report, featuring a beat but no guidance hike.

originale

benzinga.com1 g fa

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne reported $109.4M Q2 revenue (+64% YoY), $8.1M profit, 196,000 tests (+35%), maintaining $450-465M FY2026 guidance. The 28% after-hours drop despite strong results signals market repricing genomic diagnostics multiples—caution for precision medicine investments.

Leggi questa versione →

Timeline cronologica

giovedì 6 agosto 2026·benzinga.com
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)
BillionToOne stock fell after hours after reporting second-quarter financial results.
giovedì 6 agosto 2026·investors.com
Why This DNA Tester Plummeted 40%, Leading A Medtech Selloff
Medical research stocks took a bath Thursday, helped by BillionToOne's report, featuring a beat but no guidance hike.